Different Doses of Colchicine on hsCRP
- Conditions
- Coronary Artery DiseasePercutaneous Coronary Intervention
- Interventions
- Registration Number
- NCT06078904
- Lead Sponsor
- Wuhan Union Hospital, China
- Brief Summary
Colchicine reduced atherothrombotic cardiovascular events in the COLCOT and LoDoCo2 studies. US Food and Drug Administration approved colchicine as the first anti-inflammatory drug for cardiovascular diseases on June, 2023. However, there is a lack of evidence for colchicine in East Asian population with coronary heart disease, and its effectiveness and safety need further exploration. Therefore, this study aims to use different doses of colchicine to treat patients with coronary heart disease after percutaneous coronary intervention, explore the effects of different doses of colchicine on hsCRP levels, and find the optimal dose of colchicine for treating coronary heart disease in China.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- Volunteer to participate, understand and sign an informed consent form;
- Age ≥ 18 years old, regardless of gender;
- Patient diagnosed with coronary heart disease requiring percutaneous coronary intervention;
- Complete all planned percutaneous coronary intervention during hospitalization;
- Patient must be treated according to national guidelines for standard treatment of coronary heart disease.
- Known allergies to colchicine;
- Colchicine was taken within 10 days before randomization;
- Abnormal liver function test (alanine aminotransferase >3 times the upper limit of normal value);
- Abnormal renal function test (eGFR<30mL/min);
- Thrombocytopenia (platelet count <100 g/L);
- Uncontrolled infectious diseases;
- Known immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, and malignant tumor, etc;
- Pre-existing or plan for the administration of nonsteroidal anti-inflammatory drugs, hormones, immunomodulatory drugs, or chemotherapeutic drugs;
- Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives;
- Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Colchicine 0.5 MG Colchicine 0.5 MG Colchicine 0.5 MG, one pill a day, oral intake Colchicine 0.375 MG Colchicine 0.375 MG Colchicine 0.375 MG, one pill a day, oral intake Colchicine 0.25 MG Colchicine 0.25 MG Colchicine 0.25 MG, one pill a day, oral intake Placebo Placebo Placebo, one pill a day, oral intake
- Primary Outcome Measures
Name Time Method The percentage change in hsCRP 4 weeks The percentage change in hsCRP compared to baseline
- Secondary Outcome Measures
Name Time Method Major adverse cardiac and cerebrovascular event (MACCE) 4 weeks Composite endpoint of all cause death, non fatal myocardial infarction, non fatal stroke, and revascularization due to ischemia
Plasma inflammatory cytokines level 4 weeks Inflammatory cytokines (IL-1β, IL-1receptor antagonist, IL-6, IL-18, tumor necrosis factor-α, myeloperoxidase, etc)
Bleeding 4 weeks Bleeding defined according to Bleeding Academic Research Consortium
Blood drug concentrations of different doses of colchicine 4 weeks Blood drug concentrations of different doses of colchicine
Expression of inflammation-related proteins in peripheral blood mononuclear cells 4 weeks Inflammation-related proteins (nucleotide-binding oligomerization domain-like receptor protein 3, absent in melanoma 2, etc)
Trial Locations
- Locations (1)
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China